argenx干燥综合征III期研究因无效性提前终止，Vyvgart扩展预期受挫股价双位数下跌

Argenx falls as Sjögren’s setback offsets celiac drug progress | BioPharma Dive
Skip to main content
CONTINUE TO SITE ➞
Don't miss tomorrow's biopharma industry news
Let BioPharma Dive's free newsletter keep you informed, straight from your inbox.
Daily Dive
M-F
Commercialization Weekly
Every Wednesday
Gene Therapy Weekly
Every Thursday
Emerging Biotech Weekly
Every Tuesday
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Informa TechTarget
|
Healthcare Dive
MedTech Dive
PharmaVoice
Xtelligent Pharma Life Sciences
Explore our brands
An Informa TechTarget Publication
Search
People also ask
Loading questions...
An article from
Argenx falls as Sjögren’s setback offsets celiac drug progress
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more “blockbuster expansion opportunity” for Vyvgart.
Published Oct. 8, 2026
By
Kristin Jensen
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Add us on Google
Argenx shares fell by double digits on Oct. 8, 2026.
Getty Images
Dive Brief:
Argenx shares fell 15% Thursday after the Dutch biotech said its blockbuster Vyvgart medicine failed to help patients with a tough-to-treat autoimmune disease.
An independent monitoring board recommended
ending a Phase 3 study in Sjögren’s
disease “for futility” following an interim analysis, Argenx said. The timing surprised analysts, who weren’t expecting results from the trial until the second half of 2027. A separate announcement of
successful Phase 2 research
into a new drug for celiac disease failed to mollify investors.
Several analysts said they had not included sales for a Sjögren’s indication in their models because it was a high-risk proposition. But success would have brought big upside, with as much as $1.4 billion in peak sales for that use alone. The failure removes another “blockbuster expansion opportunity” for the Vyvgart franchise, William Blair analyst Matt Phipps wrote in a note to clients.
Dive Insight:
The success of Vyvgart has propelled Argenx into the ranks of the world’s most valuable biotechnology companies. Argenx boasts a market cap of around $50 billion even after Thursday’s slide, well above Biogen, a biotech founded in 1978 with a dozen approved products.
Argenx took the more unusual route of
holding onto its first successful medicine
, rather than selling itself, and has reaped the rewards. Sales of Vyvgart and a subcutaneous version called Vyvgart Hytrulo
brought in $1.5 billion
for the company just in the second quarter. Analyst estimates for overall annual peak sales for the drug — even without Sjögren’s — range from $11 billion to $17 billion.
“Given Argenx’s premium valuation, Phase 3 setbacks have historically resulted in sharp pullbacks that ultimately present buying opportunities,” Phipps wrote. He said he’s still optimistic about the chances to expand the use of Vyvgart as well as other products in Argenx’s pipeline.
There are no treatments approved to alter the course of Sjögren’s, which causes the immune system to attack moisture-producing glands and often leaves patients with fatigue, dry eyes and pain in the mouth and joints. But both Novartis and Amgen have reported
successful Phase 3 trials
of
experimental drugs for the condition
.
Argenx had been optimistic it would succeed in developing a treatment based on
Phase 2 results
released last year and early success for a similar
experimental drug from Johnson & Johnson
.
Immunovant
is also developing a medicine in the class, known as FcRn inhibitors.
This is not the first setback for Argenx as it works to expand use of the Vyvgart franchise. The company announced
study failures
in primary immune thrombocytopenia and a skin condition called pemphigus in 2023. Then in 2025, Argenx
discontinued development
of Vyvgart for thyroid eye disease.
Both Vyvgart and Vyvgart Hytrulo are currently approved to treat generalized myasthenia gravis, a muscle weakening disease. Vyvgart Hytrulo is also approved to treat chronic inflammatory demyelinating polyneuropathy.
Investors are focusing less on the other drug Argenx highlighted on Thursday, though it could still become a blockbuster. The company acquired the medicine, known as FB102, as part of a
$2.2 billion takeover of Forte Biosciences
this year. The new Phase 2 study showed it can prevent gluten-induced intestinal damage in patients with celiac disease, Argenx said.
The market has a large unmet need, TD Securities analyst Yaron Werber wrote in a note to clients. “We view today’s result as derisking a second franchise rather than merely adding another Vyvgart indication,” offering more diversity to the pipeline, he said. He models $988 million in peak sales for the drug in celiac disease.
Add us on Google
Share
Copy link
Email
LinkedIn
X/Twitter
Facebook
Print
License
Filed Under:
Clinical Trials
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Editors' picks
Yujin Kim / MedTech Dive,
original photo
courtesy of U.S. Food and Drug Administration
Tracker
5 FDA decisions to watch in the fourth quarter of 2025
Against the backdrop of a government shutdown, the agency has a series of critical decisions ahead, among them verdicts on new therapies from Novo Nordisk and Biohaven.
By BioPharma Dive staff •
Updated Sept. 30, 2025
Permission granted by Nasdaq, Inc. / Vanja Savic
Deep Dive
//
Emerging biotech
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.
By Gwendolyn Wu •
April 28, 2026
BioPharma Dive news delivered to your inbox
Get the free daily newsletter read by industry experts
Email:
Select Newsletter:
Daily Dive
M-F
Select Newsletter:
Commercialization Weekly
Every Wednesday
Select Newsletter:
Gene Therapy Weekly
Every Thursday
Select Newsletter:
Emerging Biotech Weekly
Every Tuesday
Select user consent:
By signing up to receive our newsletter, you agree to our
Terms of Use
and
Privacy Policy
. You can unsubscribe at anytime.
Sign up
A valid email address is required.
Please select at least one newsletter.
Company Announcements
View all
|
Post a press release
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Tria…
From IQVIA
October 07, 2026
Archō’s ELAVAY Cardiometabolic Report Names Eli Lilly the Company Diabetes Advocates Trust Most
From Archō Advocacy, LLC
October 07, 2026
Archō’s ELAVAY Oncology Report Names Eli Lilly the Company Cancer Advocates Trust Most
From Archō Advocacy, LLC
September 30, 2026
New Science Paper Identifies a Shared Adenosine Signaling Pathway That Causes Cardiac Fibrosis
From Greenstone Biosciences
September 24, 2026
Editors' picks
deliormanli via Getty Images
Emerging biotech
Corporate venture firms stepped in for drug startups during biotech funding pullback
According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.
By Gwendolyn Wu •
Oct. 31, 2025
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive
//
Emerging biotech
Biotech startups are built on venture capital. Track funding rounds here.
Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.
By Gwendolyn Wu, Ben Fidler, Ned Pagliarulo and Julia Himmel •
Updated Sept. 11, 2026
Latest in Clinical Trials
A Takeda spinout builds case for its Parkinson’s drug
By Jacob Bell
ArriVent collapses on disappointing lung cancer data
By Delilah Alvarado
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
By Jonathan Gardner
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
By Ben Fidler
This website is owned and operated by
Informa TechTarget
,
a global network that informs, influences and connects the world's technology buyers and sellers.
© 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. An Informa PLC company.
Privacy policy
|
Terms of use
|
Take down policy
|
Cookie Preferences / Do Not Sell